Loading
LY3537982 / Carcinoma, Non Small Cell Lung / Cisplatin · Phase 3 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospective Phase 3 randomized trial registration for olomorasib (LY3537982) combined with pembrolizumab ± chemotherapy in treatment-naïve advanced KRAS G12C-mutant NSCLC. No results are posted in this registry record; the study is currently recruiting and designed to detect differences in progression-free survival.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis; age from 18 Years. Intervention: Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab; Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab; Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed an…; Part A: LY3537982 plus Pembrolizumab; Part B: LY35379…. Compared with: Part A: Placebo plus Pembrolizumab — Placebo Comparator; Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum — Placebo Comparator. n = 1,264. 418 sites across 29 countries.
This is a prospective Phase 3 randomized trial registration for olomorasib (LY3537982) combined with pembrolizumab ± chemotherapy in treatment-naïve advanced KRAS G12C-mutant NSCLC. No results are posted in this registry record; the study is currently recruiting and designed to detect differences in progression-free survival.
No efficacy or safety results reported in this registry record; study is actively recruiting
The source did not state who this applies to in practice.
This is a clinical trial registry record describing a planned Phase 3 study with no results reported; it documents study design and enrollment targets only.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06119581). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1264 participants (ESTIMATED). Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis. Interventions: DRUG: LY3537982; DRUG: Pembrolizumab; DRUG: Placebo; DRUG: Cisplatin; DRUG: Carboplatin; DRUG: Pemetrexed. Primary outcome measures: Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE) , Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year); Part A and Part B: Progression-Free Survival (PFS) , Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year). Brief summary: The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.